A phase 1/2, two-part, multicenter (the ENDEAVOR study; NCT05419492) trial is initiated to evaluate the safety and efficacy of ETX101 in participants with mutated SCN1A DS aged 6 to 36 months. The gene discussed is SCN1A; the disease is Dravet syndrome.